Possible 承認 against 富士レビオ株式会社
For developers: integration details
You do not need this for normal browsing. Use it when integrating this enforcement record into an internal tool or AI workflow.
/api/v1/enforcements?company=%E5%AF%8C%E5%A3%AB%E3%83%AC%E3%83%93%E3%82%AA%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE&limit=10Action summary
- Company
- 富士レビオ株式会社Japanese originalOriginal: 富士レビオ株式会社
- Entity match
- Possible entity match60/100Machine extractedCompany name extracted from the Japanese public disclosure
- Governing law
- 医薬品医療機器等法医薬品医療機器等法
- Action type
- 承認承認
- Action date
- 5 December 2022
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
First approval of a general-use test reagent for simultaneous testing of the novel coronavirus and influenza.
Show original Japanese text
新型コロナウイルス・インフルエンザを同時に検査する一般用検査薬として初めての承認
Compliance context
Context neededThis is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.
Japanese regulatory disclosure under 医薬品医療機器等法.
Review the original Japanese source and determine relevance to your counterparty-risk workflow.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Evidence pack
- Extracted at
- 2026-04-28T00:01:08.792+00:00
- Evidence checked
- 2026-04-28T00:01:08.792+00:00
- Archive captured
- 2026-04-28T00:01:09.608+00:00
Show audit JSON
{
"record": {
"id": "4ff09305-3973-407c-9cf5-fcadafff2371",
"url": "https://regbase.jp/en/enforcement/other-fu-shi-rebio-20221205",
"company_name_original": "富士レビオ株式会社",
"company_name_registry": "富士レビオ株式会社",
"corporate_number": null,
"law": {
"ja": "医薬品医療機器等法",
"en": "医薬品医療機器等法"
},
"action_type": {
"ja": "承認",
"en": "承認"
},
"authority": {
"ja": "厚生労働省",
"en": "Ministry of Health, Labour and Welfare"
}
},
"entity_match": {
"status": "possible",
"confidence": 60,
"method": "extracted_japanese_name",
"method_label": "Company name extracted from the Japanese public disclosure",
"notes": null
},
"review": {
"status": "unreviewed",
"label": "Machine extracted"
},
"compliance_context": {
"severity": "Context needed",
"actionMeaning": "This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.",
"practicalNote": "Review the original Japanese source and determine relevance to your counterparty-risk workflow.",
"lawContext": "Japanese regulatory disclosure under 医薬品医療機器等法."
},
"evidence": {
"recordUrl": "https://regbase.jp/en/enforcement/other-fu-shi-rebio-20221205",
"officialSourceUrl": "https://www.mhlw.go.jp/stf/newpage_29560.html",
"archiveUrl": "https://kiroku.today/view/355c2b54a6hv1xl7",
"archiveCapturedAt": "2026-04-28T00:01:09.608+00:00",
"extractedAt": "2026-04-28T00:01:08.792+00:00",
"translatedAt": "2026-05-01T09:44:01.169+00:00",
"evidenceCheckedAt": "2026-04-28T00:01:08.792+00:00",
"generatedAt": "2026-06-19T09:12:15.852Z"
},
"limitations": [
"RegBase aggregates public Japanese government disclosures and does not provide a credit opinion.",
"English summaries are provided for reference. The original Japanese source is authoritative.",
"Possible or unresolved entity matches should be manually verified before use in a decision."
]
}The original Japanese disclosure is the authoritative record. Use possible or unresolved matches only as leads for manual review.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.